SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biogen
BIIB 168.83+2.4%3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: SDR-SI who wrote (730)9/9/1998 5:52:00 PM
From: Hong-Lee Yu  Read Replies (1) of 1686
 
Steven,

I agreed. This agreement is a win-win situation for both companies to leverage strength. Last year, I was under impression that Merck is going to help Biogen to build infrastructure in Japan when Merck announced the license of VLA-4.

It surely looks like the street is expected that Biogen either meets or beats the expectations. The confidence is very high. Most analysts have 65-75 target price.

The average expected revenues for Avonex in 1999 is about 450M. This seems low. We should know more about it when Q3 report shows up.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News